文献速递神经免疫

Fenebrutinib治疗复发型多发性硬化的2期FENopta试验

Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study.
PubMed 文献 · Lancet Neurol · 2025-01-01

FENopta是一项多中心双盲随机安慰剂对照2期试验,109例复发型多发性硬化患者按2:1随机接受口服fenebrutinib 200mg每日两次或安慰剂治疗12周。

要点

  • Fenebrutinib较安慰剂显著减少第4-12周新发T1钆增强病灶,相对减少69%。
  • 双盲期常见不良事件为肝酶升高、头痛和鼻咽炎,无严重不良事件或死亡。

核心结论

  • Fenebrutinib耐受性良好,对限制新发局灶性脑病灶具有早期、稳健且持续的效果。

研究设计与样本

  • 多中心双盲随机安慰剂对照2期试验,在欧洲和北美6国18个中心开展,109例复发型多发性硬化患者按2:1随机接受口服fenebrutinib 200mg每日两次或安慰剂治疗12周。
  • 可选开放标签扩展研究,接受fenebrutinib治疗最长192周。

主要发现

  • 双盲治疗期fenebrutinib组较安慰剂组更常见的不良事件为肝酶升高(4例[6%] vs 0)、头痛(3例[4%] vs 1例[3%])和鼻咽炎(2例[3%] vs 0)。
  • 双盲治疗期无严重不良事件或死亡发生。

临床怎么用

  • Fenebrutinib可能为复发型多发性硬化提供一种耐受性良好且能早期限制新发脑病灶的口服BTK抑制剂选择。
  • 治疗期间需关注肝酶升高、头痛和鼻咽炎等不良事件。

局限性

  • 2期试验样本量较小,需进一步研究以更全面描述fenebrutinib在复发型和非复发进展型多发性硬化中的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prospect for Bruton's tyrosine kinase (BTK) inhibition to meaningfully affect relapsing multiple sclerosis has recently been questioned due to inconsistent findings in the magnitude and sustainability of the effect of BTK inhibitors on disease activity. We assessed the safety, efficacy, and CSF drug concentrations of fenebrutinib, a highly selective, noncovalent, reversible BTK inhibitor, in patients with relapsing multiple sclerosis. METHODS: This multicentre, double-blind, randomised, placebo-controlled, phase 2 trial (FENopta) was conducted at 18 community centres and hospitals across six countries in Europe and North America. Patients with relapsing multiple sclerosis aged 18-55 years with an Expanded Disability Status Scale (EDSS) score of 0·0-5·5, and recent documented disease activity, were randomly assigned (2:1) to oral fenebrutinib (200 mg twice daily) or placebo for 12 weeks, using permuted blocks and stratified by the presence or absence of T1 gadolinium-enhancing (Gd+) lesions on the brain MRI at screening. The randomisation sequence was generated by an interactive voice or web response system and both patients and investigators were masked to treatment allocation. Participants could enter an optional open-label extension study to receive fenebrutinib for up to 192 weeks. The primary efficacy endpoint was the total number of new T1 Gd+ lesions on brain MRI at weeks 4, 8, and 12; with additional MRI assessments at 48-week intervals during the open-label extension. Efficacy analyses were done on randomised patients with evaluable post-baseline MRIs; safety analyses used the safety-evaluable population. This study is registered with ClinicalTrials.gov, NCT05119569, and EudraCT, 2021-003772-14; recruitment is closed and the trial is ongoing. FINDINGS: Between March 1, 2022 and March 29, 2023, 109 patients with relapsing multiple sclerosis were randomly assigned treatment: 73 received fenebrutinib and 36 received placebo. 106 patients had evaluable post-baseline brain MRI scans and were assessed for efficacy in the fenebrutinib group (n=70) and placebo group (n=36). The combined number of new T1 Gd+ lesions at weeks 4, 8, and 12 were 0·077 (95% CI 0·043-0·135) in the fenebrutinib group and 0·245 (0·144-0·418) in the placebo group (69% relative reduction [95% CI 34-85]; p=0·0022). During the open-label extension, through week 48, the unadjusted annualised relapse rate was 0·04 and 95 (96%) of 99 patients were relapse-free. During the double-blind treatment phase, the most common adverse events that were more frequent in the fenebrutinib group than in the placebo group were hepatic enzyme elevations (four [6%] vs 0), headache (three [4%] vs one [3%]), and nasopharyngitis (two [3%] vs 0); no serious adverse events or deaths occurred. INTERPRETATION: Fenebrutinib was well tolerated and exerted an early, robust, and sustained effect of limiting new focal brain lesions. Further studies are needed to better characterise the safety and efficacy of fenebrutinib on both relapsing multiple sclerosis and non-relapsing progressive multiple sclerosis. FUNDING: F. Hoffmann-La Roche.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Bar-Or A, Dufek M, Budincevic H, et al. Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. Lancet Neurol. 2025. PMID: 40683275. doi:10.1016/S1474-4422(25)00174-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。